BCAX · ISSUER CIK 2023658
Bicara Therapeutics Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 Bicara Therapeutics Inc. insiders reported $0.00 of open-market purchases and $1.6M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 4 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$1.6MInsider selling
−$1.6MNet open-market
Sep 10, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 202616:23 | Sep 8, 2026 | BCAX | President, COO & Interim CEO, Director | S · Sell10b5-1 | $22.90 | −17,500 | 181,641 | -9% | −$401K | ||
| Sep 10, 202616:23 | Sep 8, 2026 | BCAX | President, COO & Interim CEO, Director | M · Exercise10b5-1 | $3.79 | +17,500 | 199,141 | +10% | $66K | ||
| Aug 12, 202616:19 | Aug 10, 2026 | BCAX | Chief Financial Officer | S · Sell10b5-1 | $27.97 | −12,500 | 129,855 | -9% | −$350K | ||
| Aug 12, 202616:19 | Aug 10, 2026 | BCAX | Chief Financial Officer | M · Exercise10b5-1 | $3.79 | +12,500 | 142,355 | +10% | $47K | ||
| Aug 12, 202616:19 | Aug 10, 2026 | BCAX | Chief Executive Officer, Director | S · Sell10b5-1 | $27.98 | −10,000 | 362,152 | -3% | −$280K | ||
| Aug 12, 202616:19 | Aug 10, 2026 | BCAX | Chief Executive Officer, Director | M · Exercise10b5-1 | $3.79 | +10,000 | 372,152 | +3% | $38K | ||
| Aug 12, 202616:19 | Aug 10, 2026 | BCAX | President and COO, Director | S · Sell10b5-1 | $27.98 | −18,750 | 181,641 | -9% | −$525K | ||
| Aug 12, 202616:19 | Aug 10, 2026 | BCAX | President and COO, Director | M · Exercise10b5-1 | $3.79 | +18,750 | 200,391 | +10% | $71K |